Risk of second cancers after radiotherapy for cervical cancer

Expert Review of Anticancer Therapy

Volumn 6, Issue 1, 2006, Pages 49-57

  Ohno, Tatsuya ^a   Kakinuma, Shizuko ^a   Kato, Shingo ^a   Tsujii, Hirohiko ^a   Shimada, Yoshiya ^a  

^a NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

Author keywords

Cervical cancer; Epidemiology; Radiotherapy; Second cancer

Indexed keywords

ALKYLATING AGENT; CHLORMETHINE; PREDNISONE; PROCARBAZINE; VINCRISTINE;

ATAXIA TELANGIECTASIA; BASAL CELL NEVUS SYNDROME; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; FAMILIAL CANCER; FAMILY HISTORY; FEMALE; FOLLOW UP; GENE FUNCTION; GENE MUTATION; GENETIC DATABASE; GENETIC SUSCEPTIBILITY; HEALTH SURVEY; HEREDITY; HODGKIN DISEASE; HUMAN; INTERMETHOD COMPARISON; LEUKEMIA; LUNG CANCER; METASTASIS; MULTIVARIATE ANALYSIS; NIJMEGEN BREAKAGE SYNDROME; NONHUMAN; OVERALL SURVIVAL; PROGNOSIS; QUANTITATIVE ANALYSIS; RADIATION DOSE; RADIATION EXPOSURE; RADIATION HAZARD; RADIATION INJURY; RETINOBLASTOMA; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SECOND CANCER; SMOKING; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; SURVIVAL TIME; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE; UTERINE CERVIX CANCER; WART VIRUS; WILD TYPE; CELL TRANSFORMATION; GENETIC PREDISPOSITION; INCIDENCE; RADIATION RESPONSE; RISK FACTOR; SURVIVAL; UTERINE CERVIX TUMOR; VIRUS INFECTION;

CELL TRANSFORMATION, NEOPLASTIC; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INCIDENCE; NEOPLASMS, RADIATION-INDUCED; PAPILLOMAVIRUS INFECTIONS; RISK FACTORS; SURVIVAL; UTERINE CERVICAL NEOPLASMS;

EID: 33644847569     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.6.1.49     Document Type: Review

References (75)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 55(2), 74-108 (2005).
2. Benedet JL, Odicino F, Maisonneuve P et al. Carcinoma of the cervix uteri. Int. J. Gynaecol. Obstet. 83(Suppl. 1), 41-78 (2003).
3. Boice JD Jr, Day NE, Andersen A et al. Second cancers following radiation treatment for cervical cancer. An international collaboration among cancer registries. J. Natl Cancer Inst. 74(5), 955-975 (1985).
4. Curtis RE, Hoover RN, Kleinerman RA, Harvey EB. Second cancer following cancer of the female genital system in Connecticut, 1935-1982. Natl Cancer Inst. Monogr. 68, 113-137 (1985).
5. Storm HH. Second primary cancer after treatment for cervical cancer. Late effects after radiotherapy. Cancer 61(4), 679-688 (1988).
6. Kleinerman RA, Boice JD Jr, Storm HH et al. Second primary cancer after treatment for cervical cancer. An international cancer registries study. Cancer 76(3), 442-452 (1995).
7. Bergfeldt K, Einhorn S, Rosendahl I, Hall P. Increased risk of second primary malignancies in patients with gynecological cancer. A Swedish record-linkage study. Acta. Oncol. 34(6), 771-777 (1995).
8. Travis LB. Therapy-associated solid tumors. Acta. Oncol. 41(4), 323-333 (2002).
9. Tucker MA, Fraumeni JF Jr. Treatment-related cancers after gynecologic malignancy. Cancer 60(8 Suppl.), 2117-2122 (1987).
10. van Leeuwen FE, Travis LB. Second cancers. In: Cancer: Principles and Practice of Oncology, 6th edition. Devita VT, Hellman S, Rosenberg SA (Eds). Lippincott Williams and Wilkins, PA, USA, 2939-2964 (2001).
11. Darrington DL, Vose JM, Anderson JR et al. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. J. Clin. Oncol. 12(12), 2527-2534 (1994).
12. Ohno T, Kato S, Tsujii H et al. Second cancers after uterine cervical cancer treated with radiation therapy. J. Clin. Oncol. 23(16S), 461s (2005).
13. Boice JD Jr, Engholm G, Kleinerman RA et al. Radiation dose and second cancer risk in patients treated for cancer of the cervix. Radiat. Res. 116(1), 3-55 (1988).
14. Kaplan J, Loftus L. Bladder cancer after pelvic irradiation for cervical cancer. South Med. J. 78(9), 1068-1070 (1985).
15. Shirouzu K, Isomoto H, Morodomi T, Ogata Y, Araki Y, Kakegawa T. Clinicopathologic characteristics of large bowel cancer developing after radiotherapy for uterine cervical cancer. Dis. Colon Rectum. 37(12), 1245-1249 (1994).
16. Nuovo GJ. The role of human papillomavirus in gynecological diseases. Crit. Rev. Clin. Lab. Sci. 37(3), 183-215 (2000).
17. Brenner DJ, Curtis RE, Hall EJ, Ron E. Second malignancies in prostate carcinoma patients after radiotherapy compared with surgery. Cancer 88(2), 398-406 (2000).
18. Thompson DE, Mabuchi K, Ron E et al. Cancer incidence in atomic bomb survivors. Part II: Solid tumors, 1958-1987. Radiat. Res. 137(2 Suppl.), S17-S67 (1994).
19. Hall EJ, Wuu CS. Radiation-induced second cancers: the impact of 3D-CRT and IMRT. Int. J. Radiat. Oncol. Biol. Phys. 56(1), 83-88 (2003).
20. Boice JD Jr, Blettner M, Kleinerman RA et al. Radiation dose and leukemia risk in patients treated for cancer of the cervix. J. Natl Cancer Inst. 79(6), 1295-1311 (1987).
21. Arai T, Nakano T, Fukuhisa K et al. Second cancer after radiation therapy for cancer of the uterine cervix. Cancer 67(2), 398-405 (1991).
22. Kato H. Cancer mortality. In: Cancer in Atomic Bomb Survivors, Japanese Cancer Association, Gann Monograph on Cancer Research no. 32. Shigematsu I, Kagan A (Eds). Japan Scientific Societies Press, Tokyo, Japan. 53-74 (1986).
23. McLaughlin JK, Hrubec Z, Blot WJ, Fraumeni JF Jr. Smoking and cancer mortality among US veterans: a 26-year follow-up. Int. J. Cancer 60(2), 190-193 (1995).
24. Ng AK, Bernardo MV, Weller E et al. Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. Blood 100(6), 1989-1996 (2002).
25. van Leeuwen FE, Klokman WJ, Veer MB et al. Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood. J. Clin. Oncol. 18(3), 487-497 (2000).
26. Boice JD Jr, Harvey EB, Blettner M, et al. Cancer in the contralateral breast after radiotherapy for breast cancer. N. Engl. J. Med. 326(12), 781-785 (1992).
27. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 61(5), 759-767 (1990).
28. Sankaranarayanan K. Ionizing radiation and genetic risks. II. Nature of radiation-induced mutations in experimental mammalian in vivo systems. Mutat. Res. 258(1), 51-73 (1991).
29. Nikiforov YE, Koshoffer A, Nikiforova M, Stringer J, Fagin JA. Chromosomal breakpoint positions suggest a direct role for radiation in inducing illegitimate recombination between the ELE1 and RET genes in radiation-induced thyroid carcinomas. Oncogene 18(46), 6330-6634 (1999).
30. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 253(5015), 49-53 (1991).
31. De Benedetti VM, Travis LB, Welsh JA et al. p53 mutations in lung cancer following radiation therapy for Hodgkin's disease. Cancer Epidemiol. Biomarkers Prev. 5(2), 93-98 (1996).
32. Taylor JA, Watson MA, Devereux TR, Michels RY, Saccomanno G, Anderson M. p53 mutation hotspot in radon-associated lung cancer. Lancet 343(8889), 86-87 (1994).
33. Iwamoto KS, Fujii S, Kurata A et al. p53 mutations in tumor and non-tumor tissues of thorotrast recipients: a model for cellular selection during radiation carcinogenesis in the liver. Carcinogenesis 20(7), 1283-1291 (1999).
34. Wada I, Horiuchi H, Mori M et al. High rate of small TP53 mutations and infrequent loss of heterozygosity in malignant liver tumors associated with thorotrast: implications for α-particle carcinogenesis. Radiat. Res. 152(6 Suppl.), S125-S127 (1999).
35. Tada M, Sawamura Y, Abe H, Iggo R. Homozygous p53 gene mutation in a radiation-induced glioblastoma 10 years after treatment for an intracranial germ cell tumor: case report. Neurosurgery 40(2), 393-396 (1997).
36. Morgan WF. Is there a common mechanism underlying genomic instability, bystander effects and other nontargeted effects of exposure to ionizing radiation? Oncogene 22(45), 7094-7099 (2003).
37. Jones PA, Gonzalgo ML. Altered DNA methylation and genome instability: a new pathway to cancer? Proc. Natl Acad. Sci. USA. 94(6), 2103-2105 (1997).
38. Belinsky SA, Klinge DM, Liechty KC, March et al. Plutonium targets the p16 gene for inactivation by promoter hypermethylation in human lung adenocarcinoma. Carcinogenesis 25(6), 1063-1067 (2004).
39. Issa JP, Baylin SB, Belinsky SA. Methylation of the estrogen receptor CpG island in lung tumors is related to the specific type of carcinogen exposure. Cancer Res. 56(16), 3655-3658 (1996).
40. Huibregtse JM, Scheffner M, Beaudenon S, Howley PM. A family of proteins structurally and functionally related to the E6-AP ubiquitin-protein ligase. Proc. Natl Acad. Sci. USA. 92(7), 2563-2567 (1995).
41. Munger K, Werness BA, Dyson N, Phelps WC, Harlow E, Howley PM. Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product. EMBO J. 8(13), 4099-4105 (1989).
42. Kemp CJ, Wheldon T, Balmain A. p53-deficient mice are extremely susceptible to radiation-induced tumorigenesis. Nature Genet. 8(1), 66-69 (1994).
43. Jacks T, Fazeli A, Schmitt EM, Bronson RT, Goodell MA, Weinberg RA. Effects of an Rb mutation in the mouse. Nature 359(6393), 295-300 (1992).
44. Santin AD, Hermonat PL, Ravaggi A, Chiriva-Internati M, Pecorelli S, Parham GP. Radiation-enhanced expression of E6/E7 transforming oncogenes of human papillomavirus-16 in human cervical carcinoma. Cancer 83(11), 2346-2352 (1998).
45. Greenspan DL, Connolly DC, Wu R et al. Loss of FHIT expression in cervical carcinoma cell lines and primary tumors. Cancer Res. 57(21), 4692-4698 (1997).
46. Li J, Zhang Z, Bidder M et al. IGSF4 promoter methylation and expression silencing in human cervical cancer. Gynecol. Oncol. 96(1), 150-158 (2005).
47. Narayan G, Arias-Pulido H, Koul S et al. Frequent promoter methylation of CDH1, DAPK, RARB, and HIC1 genes in carcinoma of cervix uteri: its relationship to clinical outcome. Mol. Cancer 13(2), 24 (2003).
48. ICRP publication 79. Genetic susceptibility to cancer. Ann. ICRP. 28(1-2), 1-157 (1998).
49. Au WW, Sierra-Torres CH, Tyring SK. Acquired and genetic susceptibility to cervical cancer. Mutat. Res. 544(2-3), 361-364 (2003).
50. Wank R, Thomssen C. High risk of squamous cell carcinoma of the cervix for women with HLA-DQw3. Nature 352(6337), 723-725 (1991).
51. Storey A, Thomas M, Kalita A et al. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 393(6682), 229-234 (1998).
52. Minaguchi T, Kanamori Y, Matsushima M, Yoshikawa H, Taketani Y, Nakamura Y. No evidence of correlation between polymorphism at codon 72 of p53 and risk of cervical cancer in Japanese patients with human papillomavirus 16/18 infection. Cancer Res. 58(20), 4585-4586 (1998).
53. Brown CWM, Doll R. Mortality from cancer and other causes after radiotherapy for ankylosing spondylitis. Br. Med. J. 4(5474), 1327-1332 (1965).
54. Kato H, Schull WJ. Studies of the mortality of A-bomb survivors. 7. Mortality, 1950-1978: Part I. Cancer mortality. Radiat. Res. 90(2), 395-432 (1982).
55. Mundt AJ, Lujan AE, Rotmensch J et al. Intensity-modulated whole pelvic radiotherapy in women with gynecologic malignancies. Int. J. Radiat. Oncol. Biol. Phys. 52(5), 1330-1337 (2002).
56. Kavanagh BD, Schefter TE, Wu Q et al. Clinical application of intensity-modulated radiotherapy for locally advanced cervical cancer. Semin. Radiat. Oncol. 12(3), 260-271 (2002).
57. Nutting C, Dearnaley DP, Webb S. Intensity modulated radiation therapy: a clinical review. Br. J. Radiol. 73(869), 459-469 (2000).
58. Roeske JC, Lujan A, Rotmensch J, Waggoner SE, Yamada D, Mundt AJ. Intensity-modulated whole pelvic radiation therapy in patients with gynecologic malignancies. Int. J. Radiat. Oncol. Biol. Phys. 48(5), 1613-1621 (2000).
59. Verellen D, Vanhavere F. Risk assessment of radiation-induced malignancies based on whole-body equivalent dose estimates for IMRT treatment in the head and neck region. Radiother. Oncol. 53(3), 199-203 (1999).
60. Kry SF, Salehpour M, Followill DS, et al. The calculated risk of fatal secondary malignancies from intensity-modulated radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 62(4), 1195-1203 (2005).
61. Suit H. The Gray Lecture 2001: coming technical advances in radiation oncology. Int. J. Radiat. Oncol. Biol. Phys. 53(4), 798-809 (2002).
62. Kagei K, Tokuuye K, Okumura T et al. Long-term results of proton beam therapy for carcinoma of the uterine cervix. Int. J. Radiat. Oncol. Biol. Phys. 55(5), 1265-1271 (2003).
63. Miralbell R, Lomax A, Cella L, Schneider U. Potential reduction of the incidence of radiation-induced second cancers by using proton beams in the treatment of pediatric tumors. Int. J. Radiat. Oncol. Biol. Phys. 54(3), 824-829 (2002).
64. Landoni F, Maneo A, Colombo A, et al. Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet 350(9077), 535-540 (1997).
65. Green JA, Kirwan JM, Tierney JF et al. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. Lancet 358, 781-786 (2001).
66. Begg AC, van der Kolk PJ, Dewit L, Bartelink H. Radiosensitization by cisplatin of RIF1 tumour cells in vitro. Int. J. Radiat. Biol. Relat. Stud. Phys. Chem. Med. 50(5), 871-884 (1986).
67. Begg AC. Cisplatin and radiation: interaction probabilities and therapeutic possibilities. Int. J. Radiat. Oncol. Biol. Phys. 19(5), 1183-1189 (1990).
68. Yang LX, Douple EB, O'Hara JA, Wang HJ. Carboplatin enhances the production and persistence of radiation-induced DNA single-strand breaks. Radiat. Res. 143(3), 302-308 (1995).
69. International Agency for Research on Cancer, World Health Organization. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Overall evaluations of carcinogenicity: an updating of IARC monographs. World Health Organization, Lyon, France, 1-42(Suppl. 7), 1-440 (1987).
70. Greene MH. Is cisplatin a human carcinogen? J. Natl Cancer Inst. 84(5), 306-312 (1992).
71. Travis LB, Holowaty EJ, Bergfeldt K et al. Risk of leukemia after platinum-based chemotherapy for ovarian cancer. N. Engl. J. Med. 340(5), 351-357 (1999).
72. Travis LB, Andersson M, Gospodarowicz M et al. Treatment-associated leukemia following testicular cancer. J. Natl Cancer. Inst. 92(14), 1165-1171 (2000).
73. Travis LB, Gospodarowicz M, Curtis RE et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. J. Natl Cancer Inst. 94(3), 182-192(2002).
74. Brunetti D, Tamaro P, Fanin R et al. Family history of cancer and risk of second malignancies in young cancer patients in Trieste, Italy. Int. J. Cancer. 115(5), 814-821 (2005).
75. Matsumoto Y, Nishimura T, Hirota S, et al. Second malignancies following radiotheray: an analysis of 54 cases accumulated by mail survey in Japan. Nippon Acta. Radiologica. 62(1), 27-31 (2002).